[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356389-105":59,"doc-detail-356389-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","kras-nras-and-braf-mutational-landscape-in-serbian-early-onset-colorectal-cancer-patients-cancer-control-volume-33-1-11-2026","KRAS, NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients - Cancer Control Volume 33 - 1-11 - 2026","","Early-onset colorectal cancer (EOCRC) is rising worldwide, and Serbia shows a comparable incidence pattern. As KRAS-specific inhibitors have recently gained approval, precise mutation genotyping has become increasingly important, yet KRAS, NRAS, and BRAF mutation subtypes in Serbian EOCRC patients had not been reported. This retrospective cohort study assessed EOCRC incidence trends from 2016–2022 and characterized the KRAS/NRAS/BRAF mutational profile using qPCR-based assays and Sanger sequencing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kras-nras-and-braf-mutational-landscape-in-serbian-early-onset-colorectal-cancer-patients-cancer-control-volume-33-1-11-2026/356389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kras-nras-and-braf-mutational-landscape-in-serbian-early-onset-colorectal-cancer-patients-cancer-control-volume-33-1-11-2026/356389.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary goal of the study on Serbian early-onset colorectal cancer?","Question",{"text":112,"@type":113},"The study investigates temporal trends in EOCRC incidence in Serbia and characterizes the mutational profile of KRAS, NRAS, and BRAF in EOCRC patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were KRAS, NRAS, and BRAF mutations tested in the study?",{"text":117,"@type":113},"Molecular testing was performed on EOCRC patients using qPCR-based diagnostic assays, and a subset was further characterized using Sanger sequencing for KRAS exon 2 and BRAF V600E mutations.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about mutation frequencies and EOCRC incidence trends?",{"text":121,"@type":113},"Registry data showed an upward trend in EOCRC incidence, especially among ages 45–49. In the qPCR-tested cohort, KRAS mutations were detected in 44.3%, NRAS in 6.4%, and BRAF in 8.9%, with BRAF V600E detected in 3.7% in the sequenced subset.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356389,1790146568,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","KRAS, NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients  \nCancer Control Volume 33: 1-11 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748261426049](DOI: 10.1177/10732748261426049)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nJovana Despotovi, PhD 1 􀀁, Neda Nikoli, MD, PhD2 􀀁, Tamara Babic, PhD1 􀀁 , Milena Ugrin, PhD3, Aleksandra Ðiki Rom, MD, PhD4, Ana Damjanovi, PhD5, Aleksandra Nikolic, PhD 1 􀀁, and Sandra Dragiˇcevi, PhD 1 􀀁  \nAbstract  \nIntroduction: Early-onset colorectal cancer (EOCRC) is increasing worldwide, with Serbia showing a similar incidence compared to global trends. Precise mutation genotyping has gained importance following the recent approval of KRAS-speciﬁc inhibitors. Although KRAS, NRAS, and BRAF testing is routinely performed in Serbia, speciﬁc mutation subtypes in EOCRC patients have not yet been published. This retrospective cohort study aimed to investigate temporal trends in EOCRC incidence in Serbia and characterize the mutational proﬁle of KRAS, NRAS, and BRAF in EOCRC patients.  \nMethods: National cancer registry data from 2016 to 2022 were analyzed to assess EOCRC incidence trends. Molecular testing for KRAS, NRAS, and BRAF was performed on 681, 420, and 67 EOCRC patients, respectively, using qPCR-based diagnostic assays, complemented by Sanger sequencing on 54 cases to characterize KRAS exon 2 and BRAF V600E mutations.  \nResults: Registry data revealed a consistent upward trend in EOCRC incidence, especially in the 45-49 years’ age group. In the qPCR-tested cohort, KRAS mutations were detected in 44.3%(302/681), NRAS in 6.4%(27/420), and BRAF in 8.9%(6/67). In the sequenced subset, KRAS mutations were found in 20.4%, including G12D (36.4%), G13D (27.3%), G12 C (18.1%), and G12S/ G12 V (9.1%) variants. BRAF V600E was detected in 3.7%.  \nConclusions: We report a rise in EOCRC in Serbia, especially in ages 45-49, and recommend policy makers to lower the screening age to 45. We present the ﬁrst detailed molecular proﬁle of Serbian EOCRC and recommend that policy makers implement routine KRAS variant testing and ensure access to KRAS G12C-targeted therapies to improve personalized care.  \nKeywords  \nearly-onset, colorectal cancer, KRAS, NRAS, BRAF  \nReceived: November 12, 2025; revised: December 27, 2025; accepted: February 5, 2026.  \n1 Gene Regulation in Cancer Group, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia 2Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia  \n3Rare Disease Research and Therapeutics Development Group, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia 4Department of Pathology, Pathohistology and Medical Cytology, University Clinical Center of Serbia, Belgrade, Serbia  \n5Department for Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia  \nCorresponding Author:  \nJovana Despotovi, PhD, Gene Regulation in Cancer Group, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444A, Belgrade, Serbia.  \nEmail: [jovana.despotovic@imgge.bg.ac.rs](jovana.despotovic@imgge.bg.ac.rs)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nIntroduction  \nColorectal cancer (CRC) represents a major global ","cbCaiiuanmlYnpzs","https://ap.wps.com/l/cbCaiiuanmlYnpzs","pdf",904784,11,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What is the primary goal of the study on Serbian early-onset colorectal cancer?\",\"answer\":\"The study investigates temporal trends in EOCRC incidence in Serbia and characterizes the mutational profile of KRAS, NRAS, and BRAF in EOCRC patients.\"},{\"question\":\"How were KRAS, NRAS, and BRAF mutations tested in the study?\",\"answer\":\"Molecular testing was performed on EOCRC patients using qPCR-based diagnostic assays, and a subset was further characterized using Sanger sequencing for KRAS exon 2 and BRAF V600E mutations.\"},{\"question\":\"What did the study find about mutation frequencies and EOCRC incidence trends?\",\"answer\":\"Registry data showed an upward trend in EOCRC incidence, especially among ages 45–49. In the qPCR-tested cohort, KRAS mutations were detected in 44.3%, NRAS in 6.4%, and BRAF in 8.9%, with BRAF V600E detected in 3.7% in the sequenced subset.\"}]","KRAS, NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients - Cancer Control Volume 33 - 1-11 - 2026 | PDF",1790125141,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64796417497b16c1922ad5126ccb0415.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afbf1a9f800777af493573098cb39b8d.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/886933fbf0bc8991496cd1b925981310.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e52c44baa90581de2de0deefd14dcaf.webp",980,1268]